MEN 11270
| Supplier | Creative Peptides |
|---|---|
| Product # | R0807 |
| CAS # | 235082-52-7 |
| Pricing | Inquire |
| LabelingTarget | B2 bradykinin receptor |
| Synonyms | (2S,4R,Z)-1-((S)-1-((S)-2-((Z)-((R)-2-amino-5-guanidino-1-hydroxypentylidene)amino)-5-guanidinopentanoyl)pyrrolidine-2-carbonyl)-N-((Z)-2-(((2S,Z)-1-(((5S,8Z,10S,11Z,12aS,19aR)-10-(3-guanidinopropyl)-9,12-dihydroxy-4,19-dioxo-2,4,5,6,7,10,12a,13,13a,14,15 |
| MolecularFormula | C60H90N20O11S |
| MolecularWeight | 1299.56 |
| Sequence | RRPXGXXXXR(Modifications: Arg-1 = D-Arg, X-1 = Hyp, X-2 = Thi, X-3 = Dab, X-4 = D-Tic, X-5 = Oic, cyclized 7γ - 10α) |
| Storage | -20°C |
| Explanation | MEN 11270 is a peptide antagonist of the B2 bradykinin receptor (pKi = 10.3) and conformationally constrained cyclized analog of HOE 140 (Cat. No. 3014). It can blocks hypotension and bronchoconstriction in vivo. |
| Activity | Antagonist |
| InChI | InChI=1S/C60H90N20O11S/c61-38(14-5-20-69-58(62)63)49(83)75-40(16-7-22-71-60(66)67)54(88)77-24-8-18-44(77)56(90)79-32-36(81)28-45(79)52(86)72-30-48(82)73-42(29-37-13-9-25-92-37)51(85)76-41-19-23-68-50(84)39(15-6-21-70-59(64)65)74-53(87)46-27-34-11-3-4-17-43(34)80(46)57(91)47-26-33-10-1-2-12-35(33)31-78(47)55(41)89/h1-2,9-10,12-13,25,34,36,38-47,81H,3-8,11,14-24,26-32,61H2,(H,68,84)(H,72,86)(H,73,82)(H,74,87)(H,75,83)(H,76,85)(H4,62,63,69)(H4,64,65,70)(H4,66,67,71)/t34-,36+,38+,39-,40-,41-,42-,43-,44-,45-,46-,47+/m0/s1 |
| InChIKey | LPLBKEKLEUYDEJ-CQSFJRBESA-N |
| IsomericSMILES | C1CC[C@H]2[C@@H](C1)C[C@@H]3N2C(=O)[C@H]4CC5=CC=CC=C5CN4C(=O)[C@H](CCNC(=O)[C@@H](NC3=O)CCCN=C(N)N)NC(=O)[C@H](CC6=CC=CS6)NC(=O)CNC(=O)[C@@H]7C[C@H](CN7C(=O)[C@@H]8CCCN8C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O |
| Appearance | White lyophilised solid |